Overexpression or activation of Src proteins occurs in a number of human cancers and is frequently linked to poor clinical outcome [2–4], although the molecular mechanisms that cancer cells use to maintain and cope with elevated levels of promiscuous activated tyrosine kinases like Src are poorly understood. This evidence concerns the gene SRC and cancer.